GLP-1 for PCOS: Hormones, Cycles & Fertility Research

Women researching GLP-1 for PCOS describe what happened after starting treatment in striking terms: "my PCOS is like it is in remission." "It gave me some semblance of my life back." "Every symptom I have ever had and struggled with is gone." These are not rare reactions. They reflect what clinical research is beginning to confirm — that GLP-1 receptor agonists may do far more for PCOS than support weight loss. If you have PCOS and are trying to understand whether these medications belong in your treatment plan, here is what the evidence actually says.

The Short Answer

GLP-1 receptor agonists — including semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) — show real clinical benefits for women with PCOS beyond the scale. Research confirms improvements in insulin resistance, testosterone levels, sex hormone-binding globulin (SHBG), menstrual regularity, and spontaneous pregnancy rates. They are not yet FDA-approved specifically for PCOS. But the 2023 International Evidence-Based Guideline now formally recommends GLP-1 RAs as a treatment option for weight management in PCOS adults, following general population guidelines (Teede et al., The Journal of Clinical Endocrinology and Metabolism, 2023).

What GLP-1 Receptor Agonists Are — and Why They Matter for PCOS

GLP-1 stands for glucagon-like peptide-1. It is a hormone your gut releases after eating. It signals the pancreas to produce insulin, slows digestion, and reduces appetite. GLP-1 receptor agonists mimic this hormone. Originally developed for type 2 diabetes, semaglutide and tirzepatide are now the most widely prescribed medications in this class.

In PCOS, the connection to GLP-1 runs directly through insulin. Most women with PCOS — regardless of body weight — have some degree of insulin resistance. When cells resist insulin, the pancreas overcompensates by producing more of it. Chronically elevated insulin then signals the ovaries to overproduce androgens like testosterone. That androgen excess is what drives irregular cycles, facial hair, acne, and problems with ovulation.

GLP-1 RAs address this at the source. By improving insulin sensitivity, they reduce the hormonal signal that drives androgen overproduction. This is why women report improvements far beyond weight — regular periods, clearer skin, lower testosterone, and in some cases, restored fertility.

Semaglutide PCOS research is the most established, with multiple randomized controlled trials and meta-analyses now published. Tirzepatide PCOS data is newer but growing rapidly, as tirzepatide acts on both GLP-1 and GIP receptors, giving it a dual mechanism that may offer additional metabolic benefits. To understand howPCOS affects hormones and ovulation, our team has a full breakdown for patients at different stages of diagnosis.

What the Research Shows: GLP-1 for PCOS vs. Standard Treatments

The clinical evidence has grown substantially over the past three years. Here is what the best available data shows across the outcomes that matter most to women with PCOS.

Hormonal Effects

GLP-1 RAs significantly reduce free androgen index and total testosterone in women with PCOS (Lin et al., Scientific Reports, 2025). When combined with metformin, they raise SHBG by 10.04 nmol/L (95% CI 7.06–13.01) — a clinically meaningful shift, since higher SHBG means less free testosterone circulating in the blood (Zhao et al., Reproductive Sciences, 2025). Liraglutide specifically reduces luteinizing hormone (LH) and free androgen index while modestly increasing SHBG (Lu et al., Diabetes, Obesity and Metabolism, 2026).

Menstrual Cycle and Fertility

GLP-1 RAs improve menstrual regularity with a standardized mean difference of 1.76 (95% CI 0.28–3.24) versus control treatments (Lu et al., Diabetes, Obesity and Metabolism, 2026). A separate meta-analysis found menstrual regularity improvement (SMD 1.72, 95% CI 0.60–2.85) and a 72% higher rate of spontaneous pregnancy (RR 1.72, 95% CI 1.22–2.43) compared to metformin or placebo (Moiz et al., EClinicalMedicine, 2025). Exenatide specifically produces higher ovulation rates (RR 1.41, 95% CI 1.11–1.80) and pregnancy rates (RR 1.93, 95% CI 1.28–2.92) versus metformin (Ye et al., Reproductive Sciences, 2023).

Insulin Resistance

Across multiple meta-analyses, GLP-1 RAs produce significant reductions in HOMA-IR — a standard measure of insulin resistance — with effect sizes ranging from SMD −0.37 to −0.62 (Lin et al., Scientific Reports, 2025; Han et al., Reproductive Biomedicine Online, 2019). Adding metformin to a GLP-1 RA reduces HOMA-IR further: MD −1.58 (95% CI −2.10 to −1.06) compared to metformin alone (Zhao et al., Reproductive Sciences, 2025).

GLP-1 for PCOS vs. Metformin: Side-by-Side Data

Outcome	GLP-1 RAs Alone	Metformin Alone	GLP-1 + Metformin Combined
BMI reduction	Superior: MD −1.72 kg/m²	Standard reference	MD −0.88 kg/m² greater than metformin alone
Weight loss	Superior: SMD −1.02	Standard reference	MD −1.37 kg greater than metformin alone
Insulin resistance (HOMA-IR)	Superior: SMD −0.40 to −0.62	Standard reference	MD −1.58 greater than metformin alone
Total testosterone	Some reduction	More effective: MD −0.41	Limited data available
Menstrual regularity	SMD 1.72–1.76 improvement	Standard reference	Limited data available
Spontaneous pregnancy rate	RR 1.72 vs. metformin/placebo	Standard reference	Limited data available
Side effects	Higher nausea, vomiting, dizziness	GI upset, improves with time	Similar to GLP-1 RAs alone

Sources: Teede et al., 2023; Lin et al., 2025; Zhao et al., 2025; Moiz et al., 2025; Ye et al., 2023

Does GLP-1 Work for Lean PCOS?

This is what women with a normal BMI ask most — and the one question current research does not fully answer.

Most clinical trials on GLP-1 RAs for PCOS enrolled women with a BMI above 25 or 30. The 2023 International PCOS Guideline explicitly notes that metformin may be considered for women with PCOS and a BMI under 25 kg/m², but it does not give a specific recommendation for GLP-1 RAs in lean patients (Teede et al., The Journal of Clinical Endocrinology and Metabolism, 2023). There is simply not enough trial data in this group yet.

What we do know is that insulin resistance in PCOS is not exclusive to women with higher body weight. Research estimates that 30–40% of lean women with PCOS have measurable insulin resistance. The mechanism by which GLP-1 RAs reduce androgens and improve cycle regularity runs through insulin — not body fat directly. This means the biological rationale for using GLP-1 RAs in lean PCOS exists, even when the formal evidence trail is still thin.

In practice, some reproductive endocrinologists prescribe low-dose GLP-1 RAs off-label to lean PCOS patients who have confirmed insulin resistance markers, have not responded to metformin, or continue to have anovulatory cycles despite other treatments. If you have lean PCOS and want to explore this option, the conversation with your doctor should start with your fasting insulin level and HOMA-IR — not your weight.

What To Do If You Want to Try GLP-1 for PCOS

Request these labs first:

• Fasting insulin and fasting glucose (to calculate HOMA-IR)

• Total and free testosterone

• SHBG (sex hormone-binding globulin)

• LH and FSH ratio

• HbA1c and 2-hour glucose tolerance test if insulin resistance is suspected

• Full lipid panel

Questions to ask your reproductive endocrinologist:

• Am I a candidate for GLP-1 therapy based on my insulin markers — not just my BMI?

• Would you recommend semaglutide or tirzepatide given my specific hormone profile?

• Should I combine a GLP-1 RA with metformin, or try one at a time?

• What monitoring do you recommend in the first three months?

• What contraception do I need while on a GLP-1 RA? (Current guidelines require effective contraception during treatment due to a lack of pregnancy safety data.)

What to realistically expect in the first three months:

Most women begin on the lowest available dose, titrated up slowly to reduce nausea and vomiting (Teede et al., Human Reproduction, 2023). Insulin and testosterone levels typically begin to shift within 8–12 weeks. Menstrual regularity may take longer — some women in trials saw changes by month three, others by month six. Gradual dose escalation is the standard approach and significantly reduces side effects (Teede et al., Human Reproduction, 2023).

Insurance and cost realities:

GLP-1 RAs are not FDA-approved for PCOS. Most insurers cover them only for type 2 diabetes or obesity (BMI ≥30, or ≥27 with a documented weight-related comorbidity). If you do not meet those criteria, you will likely pay out of pocket. Costs range from approximately $150/month for oral semaglutide with manufacturer coupons to $500–$1,000/month for injectable brand-name versions. Ask your prescriber about savings programs and whether compounded versions are an option in your state.

Frequently Asked Questions

Will a GLP-1 help regulate my period even if I'm not trying to lose weight?

Possibly yes. Research shows that GLP-1 RAs improve menstrual regularity with standardized mean differences of 1.72–1.76 in clinical trials, independent of weight loss (Lu et al., Diabetes, Obesity and Metabolism, 2026; Moiz et al., EClinicalMedicine, 2025). The mechanism is hormonal — reducing insulin lowers androgen levels, which allows the hypothalamic-pituitary-ovarian axis to function more normally. That said, the magnitude of benefit varies by individual, and most trials enrolled women with higher BMIs, so results in lean PCOS are not guaranteed by the current data.

Is GLP-1 better than metformin for PCOS?

It depends on what you are treating. GLP-1 RAs outperform metformin on weight loss (SMD −1.02), BMI reduction (MD −1.72 kg/m²), and insulin resistance (Lin et al., Scientific Reports, 2025). Metformin shows a modest advantage for reducing total testosterone (MD −0.41) (Teede et al., Journal of Clinical Endocrinology and Metabolism, 2023). For menstrual regularity and spontaneous pregnancy rates, GLP-1 RAs appear stronger. Many women benefit most from both together — the combination produces greater HOMA-IR reductions than either medication alone (Zhao et al., Reproductive Sciences, 2025).

I have a normal BMI. Can I still use a GLP-1 for my PCOS?

The 2023 International PCOS Guideline does not specifically recommend or rule out GLP-1 RAs for lean patients — most trials excluded women with a BMI under 25 (Teede et al., 2023). However, lean PCOS can involve meaningful insulin resistance, and the hormonal benefits of GLP-1 RAs run through the insulin pathway, not through body fat reduction. Some reproductive endocrinologists will prescribe off-label in lean patients with confirmed insulin resistance. Start with a fasting insulin level and HOMA-IR calculation to determine whether insulin dysfunction is present.

What side effects should I expect when starting a GLP-1?

Nausea, vomiting, and dizziness are the most commonly reported side effects and occur more frequently with GLP-1 RAs than with metformin (Lin et al., Scientific Reports, 2025). Most symptoms improve significantly as the dose is titrated slowly over several weeks — gradual escalation is the standard approach and is specifically recommended to minimize GI effects (Teede et al., Human Reproduction, 2023). Serious side effects are rare but include a risk of pancreatitis; discuss your personal and family medical history with your prescriber before starting.

Ready to Talk Through Your Options?

The right treatment path for PCOS depends on your hormone panel, your insulin markers, and your fertility goals — not a one-size-fits-all protocol. The team at Aurea Fertility Center works through exactly these questions with you, using current evidence to build a plan specific to your body.Book a consultation hereto start that conversation.